200,000+ products from a single source!
sales@angenechem.com
199657-29-9 | Carbamic acid, N-[4-[(hydroxyamino)carbonyl]phenyl]-, [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester, hydrochloride (1:1)
CAS No: 199657-29-9 Catalog No: AG002C8S MDL No:MFCD28502062
Product Description
Catalog Number:
AG002C8S
Chemical Name:
Carbamic acid, N-[4-[(hydroxyamino)carbonyl]phenyl]-, [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester, hydrochloride (1:1)
CAS Number:
199657-29-9
Molecular Formula:
C24H28ClN3O4
Molecular Weight:
457.9498
MDL Number:
MFCD28502062
IUPAC Name:
[6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate;hydrochloride
InChI:
InChI=1S/C24H27N3O4.ClH/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H
InChI Key:
QKSGNWJOQMSBEP-UHFFFAOYSA-N
SMILES:
CCN(Cc1ccc2c(c1)ccc(c2)COC(=O)Nc1ccc(cc1)C(=O)NO)CC.Cl
UNII:
Z02132R2QQ
Properties
Complexity:
575
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
457.177g/mol
Formal Charge:
0
Heavy Atom Count:
32
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
457.955g/mol
Monoisotopic Mass:
457.177g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
90.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. | PloS one 20130101 |
| Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. | Annals of the rheumatic diseases 20120301 |
| The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. | Molecular medicine (Cambridge, Mass.) 20110101 |
| Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes. | Molecular medicine (Cambridge, Mass.) 20110101 |
| ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. | Anticancer research 20101101 |
| The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. | Journal of acquired immune deficiency syndromes (1999) 20100501 |
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. | The Journal of clinical investigation 20080701 |
| Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. | Gut 20080501 |
| Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. | International journal of oncology 20080101 |
| HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. | Hepatology (Baltimore, Md.) 20060301 |
| Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. | Journal of hepatology 20050201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.